Inclusion Criteria:

   - Adults (age 18-75) with chronic HBV (positive for serum hepatitis B surface antigen
   (HBsAg) or HBV DNA for at least 6 months) prior to baseline

   - Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside
   therapy with the last dose ≥ 24 weeks prior to screening are also eligible.

   - Positive or negative for hepatitis B e antigen (HBeAg)

   - HBV DNA ≥ 20,000 IU/ml (HBeAg-positive participants) and ≥ 2,000 IU/ml (HBeAg-negative
   participants)

   - Alanine aminotransferase (ALT) > 54 U/L and ≤ 400 U/L for men and > 36 U/L and ≤ 300
   U/L for women

   - Creatinine clearance ≥ 70 mL/min

   - Negative serum pregnancy test for females of childbearing potential

   - Sexually active females of childbearing potential must agree to use a
   protocol-recommended method of contraception throughout the study and for 30 days
   following the last dose of study medication

   - Lactating females must agree to discontinue nursing before initiation of study
   investigational medicinal product

Exclusion Criteria:

   - Known bridging fibrosis or cirrhosis and/or decompensated liver disease

   - Evidence of hepatocellular carcinoma

   - Significant kidney, heart, lung, neurological, autoimmune disease, or bone disease
   (eg, osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis,
   multiple bone fractures)

   - Absolute neutrophil count < 1,500/mm^3, platelet < 100,000/mm^3, hemoglobin < 10 g/dL
   (female) or < 11 g/dL (male)

   - History of severe depression or severe psychiatric disease

   - Thyroid dysfunction

   - Coinfection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)

   - Pregnant